CDXC: מקדם החזר מותאם קצב צמיחה ChromaDex Corp.

The PEG ratio demonstrates the resilience of ChromaDex Corporation (CDXC) within the defensive wellness sector, where demand for dietary supplements persists even during a recession. Niagen patents create a robust barrier against generics, strengthening the company's market position. The value of 2.64 reflects the current volume of the metric, while geopolitics are forcing the company to shift its logistics from Asia and contend with currency volatility.

The stability of ChromaDex Corporation (CDXC), driven by the absence of geopolitical risks and a focus on the US market, allows for an objective assessment of its expansion rates. This metric compares the current P/E multiple with the annual earnings growth, identifying asset undervaluation when values fall below one. By analyzing the valuation and growth balance indicator on GURU.Markets, an investor determines whether a low ratio signals a potential breakout or reflects hidden risks.